CTMX

$0.00

(

+0.00%

)
Quote details

stock

CytomX Therapeutics Inc

NASDAQ | CTMX

2.90

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$468.35M

Market Cap

5.68

P/E Ratio

0.5

EPS

$3.25

52 Week High

$0.40

52 Week Low

HEALTHCARE

Sector

CTMX Chart

Recent Chart
Price Action

CTMX Technicals

Tags:

CTMX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $138M
Total Revenue $138M
Cost Of Revenue $1.8M
Costof Goods And Services Sold $1.8M
Operating Income $25M
Selling General And Administrative $30M
Research And Development $83M
Operating Expenses $113M
Investment Income Net -
Net Interest Income $7.1M
Interest Income $7.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax $32M
Income Tax Expense $224K
Interest And Debt Expense -
Net Income From Continuing Operations $32M
Comprehensive Income Net Of Tax -
Ebit $25M
Ebitda $27M
Net Income $32M

Revenue & Profitability

Earnings Performance

CTMX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $121M
Total Current Assets $107M
Cash And Cash Equivalents At Carrying Value $38M
Cash And Short Term Investments $38M
Inventory -
Current Net Receivables $3.1M
Total Non Current Assets $13M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $583K
Intangible Assets Excluding Goodwill $583K
Goodwill $949K
Investments -
Long Term Investments -
Short Term Investments $63M
Other Current Assets $3.6M
Other Non Current Assets -
Total Liabilities $121M
Total Current Liabilities $86M
Current Accounts Payable $1.1M
Deferred Revenue -
Current Debt -
Short Term Debt $10M
Total Non Current Liabilities $35M
Capital Lease Obligations $9.4M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $9.4M
Other Current Liabilities $7.2M
Other Non Current Liabilities $4.1M
Total Shareholder Equity -$456K
Treasury Stock -
Retained Earnings -$692M
Common Stock $1K
Common Stock Shares Outstanding $85M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$86M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.8M
Capital Expenditures $310K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $100M
Cashflow From Financing $7.5M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $32M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $138M
Total Revenue $138M
Cost Of Revenue $1.8M
Costof Goods And Services Sold $1.8M
Operating Income $25M
Selling General And Administrative $30M
Research And Development $83M
Operating Expenses $113M
Investment Income Net -
Net Interest Income $7.1M
Interest Income $7.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax $32M
Income Tax Expense $224K
Interest And Debt Expense -
Net Income From Continuing Operations $32M
Comprehensive Income Net Of Tax -
Ebit $25M
Ebitda $27M
Net Income $32M

CTMX News

CTMX Profile

CytomX Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

CytomX Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in South San Francisco, California, dedicated to transforming the treatment of cancer through its proprietary Probodyâ„¢ technology platform. This technology enables the development of highly selective therapeutics designed to minimize off-tumor effects while maximizing anti-tumor activity, thus addressing significant unmet medical needs in oncology. With a robust pipeline of product candidates in various stages of clinical development, CytomX aims to enhance patient outcomes and redefine cancer treatment paradigms. The company is strategically positioned to leverage its cutting-edge technology for potential partnerships and collaborations, further expanding its reach within the biopharmaceutical landscape.

DVLT
+30.57%
$1.09
INTC
+8.87%
$33.99
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NVDA
+0.28%
$178.19
CJET
+10.63%
$0.17
F
+3.39%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
NEHC
+49.83%
$1.38
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
BURU
-3.83%
$0.13
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
AGNC
+0.81%
$9.84
DVLT
+30.57%
$1.09
INTC
+8.87%
$33.99
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NVDA
+0.28%
$178.19
CJET
+10.63%
$0.17
F
+3.39%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
NEHC
+49.83%
$1.38
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
BURU
-3.83%
$0.13
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
AGNC
+0.81%
$9.84

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.